More on ACHFF

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(OP:ACHFF)
Delayed: 0.48 +0.13 (37.14%)
Prev. Close $0.35  
Open$0.35 
52 Wk High$ 
52 Wk Low$ 
Day High$0.48 
Day Low$0.34 
P/E N/A  
EPS$ 
Volume48,500 

Friends, Peers and Foes (?): ARCH (more...)

Jun 4, 2026 07:41 AM Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
May 22, 2026 06:50 AM Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
Apr 30, 2026 07:00 AM Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
Apr 2, 2026 05:45 AM Arch Biopartners raises $600,000 in private placement offering
Apr 2, 2026 05:45 AM Arch Biopartners Closes Non-Brokered Private Placement
Mar 30, 2026 06:03 AM Arch Biopartners arranges $600,000 private placement at $0.60 per share
Mar 30, 2026 06:03 AM Arch Biopartners Arranges Non-Brokered Private Placement
Mar 24, 2026 09:13 AM Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
Feb 9, 2026 07:29 AM Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Dec 16, 2025 07:40 AM Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
View All Articles

Entities mentioned with ACHFF

View All Entities